MINNEAPOLIS, June 07, 2017 (GLOBE NEWSWIRE) — Sun BioPharma, Inc., (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced that David Kaysen, the Company’s Chief Executive Officer, is scheduled to present at the 2017 Marcum MicroCap Conference on Thursday, June 15, 2017 at 2:30 p.m. Eastern Time, in the Julliard room at The Grand Hyatt Hotel located at 109 East 42nd Street, New York, NY.
The presentation will be webcast live at http://wsw.com/webcast/marcum5/snbp and can also be accessed through the Company’s website at http://www.sunbiopharma.com. A replay of the presentation will be available and archived for 90 days.
Persons attending the Marcum conference who would like to schedule a 1-on-1 meeting with Sun BioPharma, Inc. management during such conference may do so by contacting David Kaysen at firstname.lastname@example.org or Scott Kellen at email@example.com.
About Sun BioPharma
Sun BioPharma Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The Company’s development programs target diseases of the pancreas, including pancreatic cancer and pancreatitis; the Company’s initial product candidate is SBP-101 for the treatment of patients with pancreatic cancer. The Company is currently engaged in a Phase 1 dose-escalation with SBP-101. Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, the University of Miami, the University of Florida, the Mayo Clinic Scottsdale, the Austin Health Cancer Trials Centre in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia. Further information can be found at: www.sunbiopharma.com. Sun BioPharma’s common stock is currently quoted on the OTCQB tier of the over-the-counter markets administered by the OTC Markets Group, Inc. under the symbol: SNBP.
Investor & Media Contact: